drugset / Trial / NCT01416389
A Study of LY2523355 in Participants With Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the anti-tumor activity of LY2523355 relative to ixabepilone for the treatment of metastatic or locally recurrent breast cancer using change in tumor size as a continuous measure of response.
Timeline
- Start
- 2011-08
- Primary completion
- 2012-08
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |
| Subject | litronesib | Small molecule | 5 mg/m2 | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Intravenous |